PART I . Overview We are a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. In October 2025, we announced plans to explore strategic alternatives focused on maximizing stockholder value after being unable to align with the U.S. Food and Drug Administration, or FDA, on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome in patients with relapsed and refrac...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001628280-26-021737 | EDGAR | 71K words |
| 2025-03-25 | 2024-12-31 | 0001645666-25-000010 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031494 | EDGAR | — |
| 2023-03-14 | 2022-12-31 | 0000950170-23-007871 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004085 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012525 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010498 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009369 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001628280-25-051623 | EDGAR | 51K words |
| 2025-08-13 | 2025-06-30 | 0001645666-25-000037 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001645666-25-000027 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125457 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096213 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056918 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062950 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041332 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021257 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024486 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016897 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009686 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001628280-26-023703 | EDGAR | 3K words |
| 2026-03-30 | 0001193125-26-130486 | EDGAR | — |
| 2026-03-12 | 0001628280-26-017046 | EDGAR | — |
| 2025-11-12 | 0001628280-25-051592 | EDGAR | — |
| 2025-11-07 | 0001628280-25-050671 | EDGAR | — |
| 2025-10-22 | 0001628280-25-045871 | EDGAR | — |
| 2025-10-16 | 0001628280-25-045215 | EDGAR | — |
| 2025-08-13 | 0001645666-25-000036 | EDGAR | — |
| 2025-06-23 | 0001645666-25-000029 | EDGAR | — |
| 2025-05-13 | 0001645666-25-000026 | EDGAR | — |
145 total filings indexed. 115 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001645666 |
| Ticker | KZR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.kezarlifesciences.com |
| Listed | 2018-06-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report